AIMS Microbiology, 2019, 5(2): 158-175. doi: 10.3934/microbiol.2019.2.158.

Research article

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus

1 Floral and Nursery Plants Research Unit, U.S. National Arboretum, Agricultural Research Service, ORISE - U.S. Department of Agriculture, Beltsville, MD, USA
2 Kerry’s Nursery, Miami, FL, USA
3 Animal Biosciences and Biotechnology Laboratory, U.S. Department of Agriculture, Agricultural Research Service, Beltsville, MD, USA
4 Molecular Plant Pathology Laboratory, U.S. Department of Agriculture, Agricultural Research Service, Beltsville, MD, USA

The increasing spread of antibiotic-resistant microorganisms has led to the necessity of developing alternative antimicrobial treatments. The use of peptidoglycan hydrolases is a promising approach to combat bacterial infections. In our study, we constructed a 2 kb-triple-acting fusion gene (TF) encoding the N-terminal amidase-5 domain of streptococcal LambdaSA2 prophage endolysin (D-glutamine-L-lysin endopeptidase), a mid-protein amidase-2 domain derived from the staphylococcal phage 2638A endolysin (N-acetylmuramoyl-L-alanine amidase) and the mature version (246 residues) of the Staphylococcus simulans Lysostaphin bacteriocin (glycyl-glycine endopeptidase) at the C-terminus. The TF gene was expressed in Nicotiana benthamiana plants using the non-replicating Cowpea mosaic virus (CPMV)-based vector pEAQ-HT and the replicating Alternanthera mosaic virus (AltMV)-based pGD5TGB1L8823-MCS-CP3 vector, and in Escherichia coli using pET expression vectors pET26b+ and pET28a+. The resulting poor expression of this fusion protein in plants prompted the construction of a TF gene codon-optimized for expression in tobacco plants, resulting in an improved codon adaptation index (CAI) from 0.79 (TF gene) to 0.93 (TFnt gene). Incorporation of the TFnt gene into the pEAQ-HT vector, followed by transient expression in N. benthamiana, led to accumulation of TFnt to an approximate level of 0.12 mg/g of fresh leaf weight. Antimicrobial activity of purified plant- and bacterial-produced TFnt proteins was assessed against two strains of Gram-positive Staphylococcus aureus 305 and Newman. The results showed that plant-produced TFnt protein was preferentially active against S. aureus 305, showing 14% of growth inhibition, while the bacterial-produced TFnt revealed significant antimicrobial activity against both strains, showing 68 (IC50 25 µg/ml) and 60% (IC50 71 µg/ml) growth inhibition against S. aureus 305 and Newman, respectively. Although the combination of codon optimization and transient expression using the non-replicating pEAQ-HT expression vector facilitated production of the TFnt protein in plants, the most functionally active antimicrobial protein was obtained using the prokaryotic expression system.
  Figure/Table
  Supplementary
  Article Metrics

Keywords endolysins; lysostaphin; antimicrobials; CPMV-based vector; transient expression; codon optimization; Nicotiana benthamiana

Citation: Natalia Y. Kovalskaya, Eleanor E. Herndon, Juli A. Foster-Frey, David M. Donovan, Rosemarie W. Hammond. Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus. AIMS Microbiology, 2019, 5(2): 158-175. doi: 10.3934/microbiol.2019.2.158

References

  • 1.Tong S, Davis J, Eichenberger E, et al. (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28: 603–661.    
  • 2.Kadariya J, Smith T, Thapaliya D (2014) Staphylococcus aureus and staphylococcal food-borne disease: an ongoing challenge in public health. BioMed Res Int 2014: 1–9.
  • 3.Hennekinne J, Buyder M, Dragacci S (2012) Staphylococcus aureus and its food poisoning toxins: characterization and outbreak investigation. FEMS Microbial Rev 36: 815–836.    
  • 4.Altamirano F, Barr J (2019) Phage therapy in the postantibiotic era. Clin Microbiol Rev 32: e00066–18.
  • 5.Furfaro L, Payne M, Chang B (2018) Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol 8: 1–7.    
  • 6.Lin D, Koskella B, Lin H (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8: 162–173.    
  • 7.Liu J, Wang N, Liu Y, et al. (2018) The antimicrobial spectrum of lysozyme broadened by reductive modifications. Poult Sci 97: 3992–3999.    
  • 8.Massschalck B, Michiels C (2003) Antimicrobial properties of lysozyme in relation to foodborne vegetative bacteria. Crit Rev Microbiol 29: 191–214.    
  • 9.Jagielska E, Chojnacka O, Sabała I (2016) LytM fusion with SH3b-like domain expands its activity to physiological conditions. Microb Drug Resist 22: 561–469.
  • 10.Tossavainen H, Raulinaitis V, Kauppinen L, et al. (2018) Structural and functional insights into Lysostaphin-substrate interaction. Front Mol Biosci 5: 1–14.    
  • 11.Channabasappa S, Durgaiah M, Chikkamadaiah R, et al. (2018) Efficacy of novel antistaphylococcal ectolysin P128 in a rat model of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents and Chemother 62: 1–10.
  • 12.Cooper C, Mirzael M, Nilsson A (2016) Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 7: 1–15.
  • 13.Kashani H, Schmelcher M, Sabzalipoor H, et al. (2018) Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev 31: e00071–17.
  • 14.Love M, Bhandari D, Dobson R, et al. (2018) Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care. Antibiotics 7: 1–25.
  • 15.Desbois A, Coote P (2011) Bacteriocidal synergy of Lysostaphin in combination with antimicrobial peptides. Eur J Clin Microbiol Infect Dis 30: 1015–1021.    
  • 16.Graham S, Coote P (2007) Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase Lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 59: 759–762.    
  • 17.Hjelm L, Nilvebrant J, Nygren P, et al. (2019) Lysis staphylococcal cells by modular lysin domains linked via a non-covalent barnase-barstar interaction bridge. Front Microbiol 10: 1–9.    
  • 18.Nair S, Desai S, Poonacha N, et al. (2016) Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob Agents Chemother 60: 7280–7289.
  • 19.Schmelcher M, Donovan D, Loessner M (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7: 1147–1171.    
  • 20.Roach D, Donovan D (2015) Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5: e1062590.    
  • 21.Vázquez R, García E, García P (2018) Phage lysins for fighting bacterial respiratory infections: a new generation of antimicrobials. Front Immunol 9: 1–12.    
  • 22.Briers Y, Walmagh M, Grymonprez B, et al. (2014) Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother 58: 3774–3784.    
  • 23.Larpin Y, Oechslin F, Moreillon P. et al. (2018) In vitro characterization of PlyE146, a novel hage lysin that targets Gram-negative bacteria. PLoS ONE 13: e0192507.    
  • 24.Matamp N, Bhat S (2019) Phage endolysins as potential antimicrobials against multidrug resistant Vibrio alginolyticus and Vibrio parahaemolyticus: current status of research and challenges ahead. Microorganisms 7: 1–11.
  • 25.Gerstmans H, Rodríguez-Rubio L, Lavigne R, et al. (2016) From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans 44: 123–128.    
  • 26.Pastagia M, Euler C, Chahales P, et al. (2011) A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive staphylococcus aureus strains. Antimicrob Agents Chemother 55, 738–744.
  • 27.Rodríguez-Rubio L, Martínez B, Rodríguez A, et al. (2013) The phage lytic proteins from the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 display multiple active catalytic domains and do not trigger staphylococcal resistance. PLoS One 8: e64671.    
  • 28.Becker S, Roach D, Chauhan V, et al. (2016) Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 6: 1–10.    
  • 29.Donovan D, Foster-Frey J (2008) LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5domain for antimicrobial lysis of streptococci. FEMS Microbiol Lett 287: 22–33.    
  • 30.Abaev I, Foster-Frey J, Korobova O, et al. (2013) Staphylococcal Phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site. Appl Microbiol Biotechnol 97: 3449–3456.    
  • 31.Yang X, Li C, Lou R, et al. (2007) In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing. China J Med Microbiol 56: 71–76.    
  • 32.Pritchard D, Dong S, Kirk M, et al. (2007) LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae. Appl Environ Microbiol 73: 7150–7154.    
  • 33.Lim H-S, Vaira A, Domier L, et al. (2010) Efficiency of VIGS and gene expression in a novel bipartite potexvirus vector delivery system as a function of strength of TGB1 silencing suppression. Virology 402: 149–163.    
  • 34.Peyret H, Lomonossoff G (2013) The pEAQ vector series: the easy and quick way to produce recombinant proteins in plants. Plant Mol Biol 83: 51–58.    
  • 35.Kovalskaya N, Zhao Y, Hammond R (2011) Antibacterial and antifungal activity of a snakin-defensin hybrid protein expressed in tobacco and potato plants. The Open Plant Sci J 5: 29–42.    
  • 36.Kovalskaya N, Hammond RW (2009) Expression and functional characterization of the plant antimicrobial snakin-1 and defensin recombinant proteins. Protein Expr Purif 63: 12–17.    
  • 37.Sainsbury F, Thuenemann E, Lomonossoff G. (2009) pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J 7: 682–693.    
  • 38.Scholthof H, Scholthof K-B, Jackson A (1996) Plant virus gene vectors for transient expression of foreign proteins in plants. Annu Rev Phytopathol 34: 299–323.    
  • 39.Al-Hawash A, Zhang X, Ma F (2017) Strategies of codon optimization for high-level heterologous protein expression in microbial expression systems. Gene Reports 9: 46–53.    
  • 40.Inouye S, Sahara-Miura Y, Sato J, et al. (2015) Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. Protein Expr Purif 109: 47–54.    
  • 41.Khalili M, Soleyman M, Baazm M, et al. (2015) High-level expression and purification of soluble bioactive recombinant human heparin-binding epidermal growth factor in Escherichia coli. Cell Biol Int 39: 858–864.    
  • 42.Woo J, Liu Y, Mathias A, et al. (2002) Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 25: 270–282.
  • 43.Kuta D, Tripathi L (2005) Agrobacterium-induced hypersensitive necrotic reaction in plant cells: a resistance response against Agrobacterium-mediated DNA transfer. Afr J Biotechnol 4: 752–757.
  • 44.Chen Q, Lai H, Hurtado J, et al. (2013) Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Adv Tech Biol Med 1: 1–21.
  • 45.Kovalskaya N, Foster-Frey J, Donovan D, et al. (2016) Antimicrobial activity of bacteriophages endolysin produced in Nicotiana benthamiana plants. J Microbiol Biotechnol 26: 160–170.    
  • 46.Grӓslund S, Nordlund P, Weigelt J, et al. (2008) Protein production and purification. Nature Methods 5: 135–146.    
  • 47.Vera A, González-Montalbán N, Aris A, et al. (2007) The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng 96: 1101–1106.    
  • 48.Desai P, Shrivastava N, Padh H (2010) Production of heterologous proteins in plants: strategies for optimal expression. Biotechnolo Adv 28: 427–435.    
  • 49.Dirisala V, Nair R, Srirama K, et al. (2017) Recombinant pharmaceutical protein production in plants: unraveling the therapeutic potential of molecular pharming. Acta Physiol Plant 39: 1–9.    
  • 50.Rosano G, Ceccarelli E (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5: 1–17.

 

This article has been cited by

  • 1. Michal Zeman, Pavol Bárdy, Veronika Vrbovská, Pavel Roudnický, Zbyněk Zdráhal, Vladislava Růžičková, Jiří Doškař, Roman Pantůček, New Genus Fibralongavirus in Siphoviridae Phages of Staphylococcus pseudintermedius, Viruses, 2019, 11, 12, 1143, 10.3390/v11121143
  • 2. Rosemarie W. Hammond, Steven M. Swift, Juli A. Foster-Frey, Natalia Y. Kovalskaya, David M. Donovan, Optimized production of a biologically active Clostridium perfringens glycosyl hydrolase phage endolysin PlyCP41 in plants using virus-based systemic expression, BMC Biotechnology, 2019, 19, 1, 10.1186/s12896-019-0594-7

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved